›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:DetermaTx™
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
OncocyteType:
Laboratory Developed Test
Related tests:
almost2years
DetermaTx™: Clinical launch in Q1 2023 (Oncocyte)
Investor Presentation
Launch
|
DetermaTx™
over2years
DetermaIO +DetermaTx launch estimate: For genomic profiling test in late Q1 2022 (GlobalData)
A subscription to REFINITIV is required to access document 95105979 | Page no: 81 | REPORT TITLE: "OncoCyte Corp (OCX) - Financial analysis review” | AUTHOR: Global Data, et al | DATE: 01/11/22
Launch
|
DetermaIO™ • DetermaTx™
over2years
DetermaTx™: Reimbursement dossier submission by end of Q2 2022 (Oncocyte)
Investor Presentation
Reimbursement
|
DetermaTx™
over2years
DetermaTx launch estimate: For tumor detection in Q1 2022 (GlobalData)
A subscription to REFINITIV is required to access document 94034972 | Page no: 108 | REPORT TITLE: "OncoCyte Corp (OCX) - Financial analysis review” | AUTHOR: GlobalData, et al | DATE: 12/07/21
Launch
|
DetermaTx™
over2years
DetermaTx launch estimate: For tumor detection in H1 2022 (The Benchmark Company)
"A subscription to REFINITIV is required to access document 94587787 | Page no: 01 | REPORT TITLE: "Model update for 3Q; Robust 2022 product launch schedule” | AUTHOR: Bruce D. Jackson, et al | DATE: 11/16/21"
Launch
|
DetermaTx™
Share
